Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone

3 Mar 2016

Abstract excerpt

In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Bioactive Compounds and Antitumor Agents
Share to Cancer therapeutics and mechanisms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26695512
DOI: 10.2174/0929867323666151223095839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial QuinolonePMID 26695512Read ↗

Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. HydeSemantic proximity Read ↗

Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer ActivitiesSemantic proximity Read ↗

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

New insights into the activities and toxicities of the old anticancer drug doxorubicinSemantic proximity Read ↗

Recent developments in topoisomerase-targeted cancer chemotherapySemantic proximity Read ↗

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase IISemantic proximity Read ↗

Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.Semantic proximity Read ↗

Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomeraseSemantic proximity Read ↗

Differential Targeting of Human Topoisomerase II Isoforms with Small MoleculesSemantic proximity Read ↗

Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial AgentsSemantic proximity Read ↗

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.